Zobrazeno 1 - 5
of 5
pro vyhledávání: '"OLIVIA J. SANDERS"'
Autor:
Mercedes J. Burnside, Dana M. Lewis, Hamish R. Crocket, Renee A. Meier, Jonathan A. Williman, Olivia J. Sanders, Craig A. Jefferies, Ann M. Faherty, Ryan G. Paul, Claire S. Lever, Sarah K.J. Price, Carla M. Frewen, Shirley D. Jones, Tim C. Gunn, Christina Lampey, Benjamin J. Wheeler, Martin I. de Bock
Publikováno v:
Diabetes Technology & Therapeutics. 25:250-259
Autor:
Alisa Boucsein, Antony S. Watson, Carla M. Frewen, Olivia J. Sanders, Jillian J. Haszard, Shirley D. Jones, Philippa J. Milford-Hughes, Martin I. de Bock, Benjamin J. Wheeler
Publikováno v:
Diabetes Care. 46:628-632
OBJECTIVETo evaluate glycemic outcomes in youth (aged 13–25 years) with type 1 diabetes and high-risk glycemic control (HbA1c ≥8.5% [69 mmol/mol]) on multiple daily injection (MDI) therapy after transitioning to advanced hybrid closed loop (AHCL)
Autor:
Mercedes J. Burnside, Dana M. Lewis, Hamish R. Crocket, Renee A. Meier, Jonathan A. Williman, Olivia J. Sanders, Craig A. Jefferies, Ann M. Faherty, Ryan G. Paul, Claire S. Lever, Sarah K.J. Price, Carla M. Frewen, Shirley D. Jones, Tim C. Gunn, Christina Lampey, Benjamin J. Wheeler, Martin I. de Bock
Publikováno v:
New England Journal of Medicine. 387:869-881
Open-source automated insulin delivery (AID) systems are used by many patients with type 1 diabetes. Data are needed on the efficacy and safety of an open-source AID system.In this multicenter, open-label, randomized, controlled trial, we assigned pa
Autor:
Benjamin J. Wheeler, Martin I. de Bock, Philippa J. Milford-Hughes, Shirley D. Jones, Jillian J. Haszard, Olivia J. Sanders, Carla M Frewen, Antony S. Watson, Alisa Boucsein
Objective: To evaluate glycemic outcomes in youth (aged 13–25 years) with type 1 diabetes and high-risk glycemic control [HbA1c ≥ 8.5% (69 mmol/mol)] on multiple daily injections (MDI) after transitioning to advanced hybrid closed-loop (AHCL) the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62b8c5df66bb8ba64b8af7ded1daf23a
https://doi.org/10.2337/figshare.21785207
https://doi.org/10.2337/figshare.21785207
Autor:
MERCEDES J. BURNSIDE, DANA M. LEWIS, HAMISH CROCKET, RENEE MEIER, JONATHAN WILLIMAN, OLIVIA J. SANDERS, CRAIG A. JEFFERIES, ANN M. FAHERTY, RYAN PAUL, CLAIRE S. LEVER, BENJAMIN J. WHEELER, SHIRLEY JONES, CARLA M. FREWEN, TIM GUNN, CHRISTINA LAMPEY, MARTIN DE BOCK
Publikováno v:
Diabetes. 71
Objective: Open-source automated insulin delivery (AID) pre-dated the availability of commercial systems and is used by thousands of people with T1D despite no regulatory approval. Our objective was to examine efficacy and safety of open-source AID.